Eduardo Ticona1, Marta E Bull, Jaime Soria, Kenneth Tapia, Jillian Legard, Sheila M Styrchak, Corey Williams, Caroline Mitchell, Alberto La Rosa, Alberto L A Rosa, Robert W Coombs, Lisa M Frenkel. 1. aHospital Nacional dos de Mayo, Lima, Peru bDepartment of Pediatrics, University of Washington cCenter for Global Infectious Disease Research, Seattle Children's Hospital Research Institute dDepartment of Global Health eDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington fInvestigaciones Médicas en Salud (INMENSA), Lima, Peru gDepartment of Medicine hDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA. *Eduardo Ticonaa and Marta E. Bull contributed equally to the writing of this article. †Currently involved with the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS) program, Seattle Children's Hospital, Seattle, Washington, USA. ‡Currently with the Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: Inflammatory biomarkers associated with cardiovascular disease are elevated in HIV-infected persons. These biomarkers improve with antiretroviral therapy (ART) but do not normalize to values observed in HIV-uninfected adults. Little is known regarding biomarkers of inflammation in HIV-infected Peruvians, in whom an increased burden of infectious diseases may exacerbate inflammation, and women, in whom sex difference may alter inflammation compared with men. METHODS: Peruvians initiating first-line ART were enrolled in a prospective observational study. Individuals with suppression of HIV RNA plasma loads to less than 30 copies/ml when determined quarterly over 24 months of ART, had biomarkers of inflammation and cellular activation measured pre-ART and at 24-months of ART, and evaluated for associations with sex and clinical parameters. RESULTS: Pre-ART high-sensitivity C-reactive protein (hsCRP) values of men were in the high-risk cardiovascular disease category (>3.0 mg/l) more frequently compared with women (P = 0.02); most women's values were in the low/average-risk categories. At 24 months of suppressive ART, hsCRP concentrations decreased in men (P = 0.03), but tended to increase in women, such that the proportion with high-risk hsCRP did not differ by sex. Pre-ART, soluble CD163 concentrations were higher in women compared with men (P = 0.02), and remained higher after 24 months of suppressive ART (P = 0.02). All other inflammatory biomarkers (P < 0.03) decreased across sexes. Biomarker concentrations were not associated with BMI or coinfections. CONCLUSION: Elevated inflammatory biomarkers persisted despite 24 months of suppressive ART in a subset of Peruvians, and to a greater extent in women compared with men. These findings suggest that lifestyle or pharmacologic interventions may be required to optimize the health of HIV-infected Peruvians, particularly women.
OBJECTIVE: Inflammatory biomarkers associated with cardiovascular disease are elevated in HIV-infectedpersons. These biomarkers improve with antiretroviral therapy (ART) but do not normalize to values observed in HIV-uninfected adults. Little is known regarding biomarkers of inflammation in HIV-infected Peruvians, in whom an increased burden of infectious diseases may exacerbate inflammation, and women, in whom sex difference may alter inflammation compared with men. METHODS: Peruvians initiating first-line ART were enrolled in a prospective observational study. Individuals with suppression of HIV RNA plasma loads to less than 30 copies/ml when determined quarterly over 24 months of ART, had biomarkers of inflammation and cellular activation measured pre-ART and at 24-months of ART, and evaluated for associations with sex and clinical parameters. RESULTS: Pre-ART high-sensitivity C-reactive protein (hsCRP) values of men were in the high-risk cardiovascular disease category (>3.0 mg/l) more frequently compared with women (P = 0.02); most women's values were in the low/average-risk categories. At 24 months of suppressive ART, hsCRP concentrations decreased in men (P = 0.03), but tended to increase in women, such that the proportion with high-risk hsCRP did not differ by sex. Pre-ART, soluble CD163 concentrations were higher in women compared with men (P = 0.02), and remained higher after 24 months of suppressive ART (P = 0.02). All other inflammatory biomarkers (P < 0.03) decreased across sexes. Biomarker concentrations were not associated with BMI or coinfections. CONCLUSION: Elevated inflammatory biomarkers persisted despite 24 months of suppressive ART in a subset of Peruvians, and to a greater extent in women compared with men. These findings suggest that lifestyle or pharmacologic interventions may be required to optimize the health of HIV-infected Peruvians, particularly women.
Authors: Frank J Palella; Stephen J Gange; Lorie Benning; Lisa Jacobson; Robert C Kaplan; Alan L Landay; Russell P Tracy; Richard Elion Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Babafemi Taiwo; Roy M Matining; Lu Zheng; Michael M Lederman; Charles R Rinaldo; Peter S Kim; Baiba I Berzins; Daniel R Kuritzkes; Amy Jennings; Joseph J Eron; Cara C Wilson Journal: J Antimicrob Chemother Date: 2013-04-18 Impact factor: 5.790
Authors: Paul K Drain; Roland Kupka; Gernard I Msamanga; Willy Urassa; Ferdinand Mugusi; Wafaie W Fawzi Journal: AIDS Date: 2007-10-01 Impact factor: 4.177
Authors: Antonio Bernabe-Ortiz; Catherine Pastorius Benziger; Robert H Gilman; Liam Smeeth; J Jaime Miranda Journal: PLoS One Date: 2012-04-05 Impact factor: 3.240
Authors: Maria L Alcaide; Anita Parmigiani; Suresh Pallikkuth; Margaret Roach; Riccardo Freguja; Marina Della Negra; Hector Bolivar; Margaret A Fischl; Savita Pahwa Journal: PLoS One Date: 2013-05-28 Impact factor: 3.240
Authors: Leah H Rubin; Lorie Benning; Sheila M Keating; Philip J Norris; Jane Burke-Miller; Antonia Savarese; Krithika N Kumanan; Saria Awadalla; Gayle Springer; Kathyrn Anastos; Mary Young; Joel Milam; Victor G Valcour; Kathleen M Weber; Pauline M Maki Journal: J Neurovirol Date: 2017-10-23 Impact factor: 2.643
Authors: Christophe Vanpouille; Alan Wells; Timothy Wilkin; Jyoti S Mathad; Sheldon Morris; Leonid Margolis; Sara Gianella Journal: AIDS Date: 2022-05-25 Impact factor: 4.632
Authors: Mabel Toribio; Magid Awadalla; Madeline Cetlin; Evelynne S Fulda; Takara L Stanley; Zsofia D Drobni; Lidia S Szczepaniak; Michael D Nelson; Michael Jerosch-Herold; Tricia H Burdo; Tomas G Neilan; Markella V Zanni Journal: J Acquir Immune Defic Syndr Date: 2020-10-01 Impact factor: 3.731
Authors: Sara H Bares; Laura M Smeaton; Sarah E Scott; Beth A Smith; Catherine Godfrey; Grace A McComsey Journal: J Infect Dis Date: 2021-11-22 Impact factor: 7.759
Authors: Marta E Bull; Caroline Mitchell; Jaime Soria; Sheila Styrchak; Corey Williams-Wietzikoski; Jillian Legard; Jennifer McKernan-Mullin; Kelli Kraft; Frankline Onchiri; Joshua Stern; Sarah Holte; Kevin J Ryan; Edward P Acosta; Alberto La Rosa; Robert W Coombs; Eduardo Ticona; Lisa M Frenkel Journal: AIDS Date: 2018-07-17 Impact factor: 4.177